Prokidney to present at the jefferies cell and genetic medicine summit

Winston-salem, n.c., sept. 23, 2022 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced that dr. tim bertram, chief executive officer of prokidney, will present a corporate overview at the jefferies cell and genetic medicine summit at 1:30 p.m. et on thursday, september 29, 2022, in new york, ny.
PROK Ratings Summary
PROK Quant Ranking